In 2024, the ataxia market was valued at USD 37.70 billion. With growing research and drug approvals, this market is projected to expand at a 9.72% C ...

Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.